MONTVALE, N. J. — January 7, 2026 — Leads & Copy — EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”), a biotechnology company, announced plans for clinical trials in cancer cachexia, inflammatory bowel disease, and retinal disorders.
EOM plans to initiate a Phase II exploratory clinical trial in patients with Crohn’s disease and reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients. The company also provided an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147.
The Crohn’s disease trial is designed to include 15-20 patients at clinical sites in New Brunswick and Lakewood, NJ, under Principal Investigator Arkady Broder, MD, Director of Gastroenterology at the St. Peter’s Healthcare System. It will enroll subjects with moderate to severe Crohn’s disease who have failed or could not tolerate at least one conventional therapy. EOM anticipates initiating the trial in the first quarter 2026 to test for signs of clinical remission and endoscopic remission with EOM613 treatment and to measure biomarkers such as C-reactive protein, calprotectin and pro-inflammatory serum cytokines.
The IND application is for an open-label Phase II trial with Stage 4 cancer patients to be treated with EOM613 daily for 26 weeks. The trial’s Principal Investigator is Azriel Hirschfeld, MD, at Hirschfeld Oncology in Brooklyn, NY. There is currently no approved drug for the treatment of cancer cachexia in the United States.
In 2025, EOM completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with favorable results. No adverse drug-related toxic effects were seen with daily subcutaneous injections of EOM613 for 28 consecutive days, including at 13.5 times the highest anticipated dosing levels in humans. No adverse effects were seen in tissue upon histopathological testing. These data, combined with previously reported promising results of a Phase I/IIa 2023 human clinical trial in hospitalized COVID-19 patients with cytokine-driven respiratory inflammation in Brazil, support the Crohn’s disease trial.
EOM147 is a first-in-class small molecule anti-angiogenic drug for the treatment of proliferative diabetic retinopathy, diabetic macular edema, branch and central retinal vein occlusions, and wet age-related macular degeneration (AMD). Novel chemically stable eye drop formulations have been developed for the EOM147 active pharmaceutical ingredient (API). The GMP manufacture of the API via a scalable synthesis route is currently being carried out at a contracted manufacturing site to support the required nonclinical animal studies of bioanalytical measurement of the drug in plasma, and ocular toxicity studies/ocular tissue drug uptake. These specialized nonclinical studies are anticipated to begin in the first quarter of 2026 in Quebec, Canada. EOM intends to conduct Phase I/II trials with the novel eye drop formulation of EOM147 in retinal vein occlusions (RVO) in the United States, and in diabetic retinopathy (DR) in Mexico and India, pending favorable results.
EOM Chief Executive Officer Dr. Irach Taraporewala said that completing the development of the novel eye drop formulations is an important step forward for the company. He believes the eye drop has the potential to become a new approach to the treatment of multiple angiogenic retinal diseases and could replace the need for periodic intraocular injections.
EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and anti-inflammatory cytokines with potential therapeutic utility in treating a variety of acute and chronic inflammatory conditions. EOM147 is being developed as a proprietary, newly reformulated eye drop containing a steroid-polyamine conjugate small molecule with anti-angiogenic activity, which targets multiple angiogenic growth factors through a calmodulin-mediated mechanism.
Wayne I. Danson, Chief Financial Officer, can be contacted at info@eompharma.com.
Source: EOM Pharmaceutical Holdings, Inc.
